Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Ugel, stefano (2008) Approcci di immunoterapia attiva e passiva basati sull'antigene telomerasi in modelli di carcinogenesi murina. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
1582Kb

Abstract (inglese)

Aim of this work was to verify the therapeutic efficacy of active and passive vaccination against m-TERT in mice bearing transplantable tumors and in an autochthonous mouse model of prostate cancer: the TRAMP model. To choose the best vaccination protocol we developed DNA-based antigen-specific expression systems employing eukaryotic plasmid expression vectors and recombinant adenoviruses. We used splenocytes from vaccinated mice to set up mixed leukocyte peptide cultures (MLPC) with the mouse (m)-TERT198-205 peptide. This sequence of mouse TERT was identified as the immunodominant epitope by screening overlapping peptides covering the whole protein. MLPC were tested in IFN?-specific E.L.IS.A. assay against peptide-pulsed cells and unpulsed tumor cell lines of different histotypes, but with the same H-2b haplotype. A persistently high level of recognition was noted against peptidepulsed cell lines, whereas repeated in vitro stimulation with ?-irradiated syngeneic splenocytes pulsed with a low dose of m-TERT198-205 peptide (0.1 ?M) every week led to an increased recognition of unpulsed tumor cell lines. This enhanced recognition was observed only in MLPC from mice vaccinated with DNA plasmid vector and suggested a preferential proliferation of high-avidity CTL clones under these culture conditions. The augment in high-avidity CTLs is supported by TCR analysis by spectratyping, that proved a positive selection of V?-11 chain of TCR during in vitro passages together with TCR clonotype enrichment. We demonstrated an important therapeutic effect by m-TERT198-205 polyclonal CTLs transfer in a metastatic melanoma model, where mice treated with CTLs transfer presented a significant reduction of the lung metastases compared with untreated controls, and in trasplantable tumor models, where TERT198-205 CTLs induced a statistically significant delay in tumor growth and a survival increase in both melanoma- and prostate carcinoma-bearing mice.
To identify and isolate high affinity CTL clones specific for m-TERT198-205 epitope we used the limiting dilution technique starting from the polyclonal CTLs. We obtained a large spectrum of clones, among which clone CTL-7 was the most intriguing. In fact it was able to recognize tumor cell lines of different histotypes (melanoma, prostate carcinoma, colon carcinoma and sarcoma) as well as peptidepulsed cell lines. Transfer of CTL-7 clone exerted a better therapeutic effect on lung metastases generated by melanoma cells.
We also investigated the possibility to elicit a protective antitumor response through an active immunization in TRAMP mice. We performed a cycle of two biweekly i.m. injections of a plasmid encoding m-TERT repeated every 10 weeks for the entire life of the mouse. Mice vaccinated against m-TERT showed a reduction of tumor progression at week 24th and a survival prolongation compared to mock vector-treated groups.
These data represent a good platform to translate more effective vaccines for the therapy of human cancers.


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Bronte, Vincenzo
Dottorato (corsi e scuole):Ciclo 20 > Corsi per il 20simo ciclo > ONCOLOGIA E ONCOLOGIA CHIRURGICA
Data di deposito della tesi:30 Gennaio 2008
Anno di Pubblicazione:30 Gennaio 2008
Parole chiave (italiano / inglese):Vaccinazione antitumorale, TRAMp, telomrasi, trasferimento adottivo di linfociti citotossici
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/06 Oncologia medica
Struttura di riferimento:Dipartimenti > pre 2012 - Dipartimento di Scienze Oncologiche e Chirurgiche
Codice ID:429
Depositato il:24 Set 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Acuto, O. and F. Michel (2003). "CD28-mediated co-stimulation: a quantitative support for TCR signalling." Nat Rev Immunol 3(12): 939-51. Cerca con Google

2. Appay, V., P. R. Dunbar, et al. (2002). "Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections." Nat Med 8(4): 379-85. Cerca con Google

3. Bach, E. A., M. Aguet, et al. (1997). "The IFN gamma receptor: a paradigm for cytokine receptor signaling." Annu Rev Immunol 15: 563-91. Cerca con Google

4. Bacich, D. J., J. T. Pinto, et al. (2001). "Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostatespecific membrane antigen/NAALADase/folate hydrolase." Mamm Genome 12(2): 117-23. Cerca con Google

5. Baniyash, M. (2004). "TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response." Nat Rev Immunol 4(9): 675-87. Cerca con Google

6. Bernhardt, S. L., M. K. Gjertsen, et al. (2006). "Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study." Br J Cancer 95(11): 1474-82. Cerca con Google

7. Bronte, V., E. Apolloni, et al. (2000). "Identification of a CD11b(+)/Gr- 1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells." Blood 96(12): 3838-46. Cerca con Google

8. Bronte, V., S. Cingarlini, et al. (2003). "Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase." J Immunol 171(12): 6396-405. Cerca con Google

9. Bronte, V., T. Kasic, et al. (2005). "Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers." J Exp Med 201(8): 1257-68. Cerca con Google

10. Bronte, V., P. Serafini, et al. (2003). "L-arginine metabolism in myeloid cells controls T-lymphocyte functions." Trends Immunol 24(6): 302-6. Cerca con Google

11. Bronte, V. and P. Zanovello (2005). "Regulation of immune responses by Larginine metabolism." Nat Rev Immunol 5(8): 641-54. Cerca con Google

12. Bui, J. D. and R. D. Schreiber (2007). "Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?" Curr Opin Immunol 19(2): 203-8. Cerca con Google

13. Burnet, F. M. (1970). "The concept of immunological surveillance." Prog Exp Tumor Res 13: 1-27. Cerca con Google

14. Burnet, M. (1964). "Immunological Factors in the Process of Carcinogenesis." Br Med Bull 20: 154-8. Cerca con Google

15. Burstein, N. A. and L. W. Law (1971). "Neonatal thymectomy and non-viral mammary tumours in mice." Nature 231(5303): 450-2. Cerca con Google

16. Calarota, S. A. and D. B. Weiner (2004). "Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants." Immunol Rev 199: 84- 99. Cerca con Google

17. Cheever, M. A., P. D. Greenberg, et al. (1980). "Specificity of adoptive chemoimmunotherapy of established syngeneic tumors." J Immunol 125(2): 711-4. Cerca con Google

18. Choudhury, A., S. Mosolits, et al. (2006). "Clinical results of vaccine therapy for cancer: learning from history for improving the future." Adv Cancer Res 95: 147-202. Cerca con Google

19. Cohen, C. J., Z. Zheng, et al. (2005). "Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR." J Immunol 175(9): 5799-808. Cerca con Google

20. Cohen, E. P. (2001). "DNA-based vaccines for the treatment of cancer—an experimental model." Trends Mol Med 7(4): 175-9. Cerca con Google

21. Colombo, M. P. and S. Piconese (2007). "Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy." Nat Rev Cancer 7(11): 880-7. Cerca con Google

22. Comoli, P., R. De Palma, et al. (2004). "Adoptive transfer of allogeneic Epstein- Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma." Ann Oncol 15(1): 113-7. Cerca con Google

23. Cong, Y. S., W. E. Wright, et al. (2002). "Human telomerase and its regulation." Microbiol Mol Biol Rev 66(3): 407-25, table of contents. Cerca con Google

24. Cortez-Gonzalez, X. and M. Zanetti (2007). "Telomerase immunity from bench to bedside: round one." J Transl Med 5: 12. Cerca con Google

25. De, A. K., C. L. Miller-Graziano, et al. (2005). "Selective activation of peripheral blood T cell subsets by endotoxin infusion in healthy human subjects corresponds to differential chemokine activation." J Immunol 175(9): 6155-62. Cerca con Google

26. De Palma, R., I. Marigo, et al. (2004). "Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes." Cancer Res 64(21): 8068- 76. Cerca con Google

27. Dighe, A. S., E. Richards, et al. (1994). "Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors." Immunity 1(6): 447-56. Cerca con Google

28. Doe, B., M. Selby, et al. (1996). "Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells." Proc Natl Acad Sci U S A 93(16): 8578-83. Cerca con Google

29. Dudley, M. E., J. R. Wunderlich, et al. (2002). "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes." Science 298(5594): 850-4. Cerca con Google

30. Dudley, M. E., J. R. Wunderlich, et al. (2002). "A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic Cerca con Google

31. melanoma." J Immunother (1997) 25(3): 243-51. Cerca con Google

32. Dunn, G. P., A. T. Bruce, et al. (2002). "Cancer immunoediting: from immunosurveillance to tumor escape." Nat Immunol 3(11): 991-8. Cerca con Google

33. Dunn, G. P., C. M. Koebel, et al. (2006). "Interferons, immunity and cancer immunoediting." Nat Rev Immunol 6(11): 836-48. Cerca con Google

34. Dunn, G. P., L. J. Old, et al. (2004). "The immunobiology of cancer immunosurveillance and immunoediting." Immunity 21(2): 137-48. Cerca con Google

35. Eng, M. H., L. G. Charles, et al. (1999). "Early castration reduces prostatic carcinogenesis in transgenic mice." Urology 54(6): 1112-9. Cerca con Google

36. Engel, A. M., I. M. Svane, et al. (1997). "MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice." Scand J Immunol 45(5): 463-70. Cerca con Google

37. Fetsch, P. A., F. M. Marincola, et al. (1999). "The new melanoma markers: MART-1 and Melan-A (the NIH experience)." Am J Surg Pathol 23(5): 607-10. Cerca con Google

38. Feunou, P., L. Poulin, et al. (2003). "CD4+CD25+ and CD4+CD25- T cells act respectively as inducer and effector T suppressor cells in superantigeninduced tolerance." J Immunol 171(7): 3475-84. Cerca con Google

39. Filaci, G., M. Fravega, et al. (2006). "Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer." Blood 107(4): 1505-12. Cerca con Google

40. Finn, O. J. (2003). "Cancer vaccines: between the idea and the reality." Nat Rev Immunol 3(8): 630-41. Cerca con Google

41. Foster, B. A., J. R. Gingrich, et al. (1997). "Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model." Cancer Res 57(16): 3325-30. Cerca con Google

42. Gabrilovich, D. (2004). "Mechanisms and functional significance of tumourinduced dendritic-cell defects." Nat Rev Immunol 4(12): 941-52. Cerca con Google

43. Gattinoni, L., C. A. Klebanoff, et al. (2005). "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells." J Clin Invest 115(6): 1616-26. Cerca con Google

44. Gattinoni, L., D. J. Powell, Jr., et al. (2006). "Adoptive immunotherapy for cancer: building on success." Nat Rev Immunol 6(5): 383-93. Cerca con Google

45. Gelbard, A., C. T. Garnett, et al. (2006). "Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis." Clin Cancer Res 12(6): 1897-905. Cerca con Google

46. Gingrich, J. R., R. J. Barrios, et al. (1996). "Metastatic prostate cancer in a transgenic mouse." Cancer Res 56(18): 4096-102. Cerca con Google

47. Grabert, R. C., L. P. Cousens, et al. (2006). "Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation." Clin Cancer Res 12(2): 569-76. Cerca con Google

48. Grant, G. A. and J. F. Miller (1965). "Effect of neonatal thymectomy on the induction of sarcomata in C57 BL mice." Nature 205(976): 1124-5. Cerca con Google

49. Greenberg, N. M., F. DeMayo, et al. (1995). "Prostate cancer in a transgenic mouse." Proc Natl Acad Sci U S A 92(8): 3439-43. Cerca con Google

50. Gross, D. A., S. Graff-Dubois, et al. (2004). "High vaccination efficiency of lowaffinity epitopes in antitumor immunotherapy." J Clin Invest 113(3): 425- 33. Cerca con Google

51. Grover, A., G. J. Kim, et al. (2006). "Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes." Clin Cancer Res 12(19): 5801-8. Cerca con Google

52. Hahn, W. C. and M. Meyerson (2001). "Telomerase activation, cellular immortalization and cancer." Ann Med 33(2): 123-9. Cerca con Google

53. Harlin, H., T. V. Kuna, et al. (2006). "Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites." Cancer Immunol Immunother 55(10): 1185-97. Cerca con Google

54. Hastie, N. D., M. Dempster, et al. (1990). "Telomere reduction in human colorectal carcinoma and with ageing." Nature 346(6287): 866-8. Cerca con Google

55. Hendriks, J., L. A. Gravestein, et al. (2000). "CD27 is required for generation and long-term maintenance of T cell immunity." Nat Immunol 1(5): 433-40. Cerca con Google

56. Hildeman, D. A., T. Mitchell, et al. (2003). "Control of Bcl-2 expression by reactive oxygen species." Proc Natl Acad Sci U S A 100(25): 15035-40. Cerca con Google

57. Hsu, F. J., C. Benike, et al. (1996). "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells." Nat Med 2(1): 52-8. Cerca con Google

58. Hu, H. M., H. Winter, et al. (2000). "Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy." J Immunol 165(8): 4246-53. Cerca con Google

59. Huang, X., M. Bennett, et al. (2004). "Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostatespecific membrane antigen." Prostate 61(1): 1-11. Cerca con Google

60. Hubert, R. S., I. Vivanco, et al. (1999). "STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors." Proc Natl Acad Sci U S A 96(25): 14523-8. Cerca con Google

61. Kaech, S. M., J. T. Tan, et al. (2003). "Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells." Nat Immunol 4(12): 1191-8. Cerca con Google

62. Kagamu, H., J. E. Touhalisky, et al. (1996). "Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes." Cancer Res 56(19): 4338-42. Cerca con Google

63. Kanegane, H., K. Nomura, et al. (2002). "Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies." Crit Rev Oncol Hematol 44(3): 239-49. Cerca con Google

64. Kaplan-Lefko, P. J., T. M. Chen, et al. (2003). "Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model." Prostate 55(3): 219-37. Cerca con Google

65. Kaplan, D. H., V. Shankaran, et al. (1998). "Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice." Proc Natl Acad Sci U S A 95(13): 7556-61. Cerca con Google

66. Kawakami, Y., M. I. Nishimura, et al. (1993). "T-cell recognition of human melanoma antigens." J Immunother Emphasis Tumor Immunol 14(2): 88- 93. Cerca con Google

67. Kershaw, M. H., M. W. Teng, et al. (2005). "Supernatural T cells: genetic modification of T cells for cancer therapy." Nat Rev Immunol 5(12): 928- 40. Cerca con Google

68. Khong, H. T. and N. P. Restifo (2002). "Natural selection of tumor variants in the generation of "tumor escape" phenotypes." Nat Immunol 3(11): 999-1005. Cerca con Google

69. Kieper, W. C., A. Troy, et al. (2005). "Recent immune status determines the source of antigens that drive homeostatic T cell expansion." J Immunol 174(6): 3158-63. Cerca con Google

70. Kim, N. W., M. A. Piatyszek, et al. (1994). "Specific association of human telomerase activity with immortal cells and cancer." Science 266(5193): 2011-5. Cerca con Google

71. Klebanoff, C. A., H. T. Khong, et al. (2005). "Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy." Trends Immunol 26(2): 111-7. Cerca con Google

72. Klein, G. (1966). "Tumor antigens." Annu Rev Microbiol 20: 223-52. Cerca con Google

73. Kobayashi, Y., T. Higashi, et al. (2000). "Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma." J Hepatol 32(4): 612-7. Cerca con Google

74. Koya, R. C., N. Kasahara, et al. (2003). "Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery." J Immunother (1997) 26(5): 451-60. Cerca con Google

75. Krieg, A. M. (2002). "CpG motifs in bacterial DNA and their immune effects." Annu Rev Immunol 20: 709-60. Cerca con Google

76. Kuball, J., F. W. Schmitz, et al. (2005). "Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a highaffinity p53A2.1-specific TCR." Immunity 22(1): 117-29. Cerca con Google

77. Lanzavecchia, A. and F. Sallusto (2002). "Progressive differentiation and selection of the fittest in the immune response." Nat Rev Immunol 2(12): 982-7. Cerca con Google

78. Larin, S. S., G. P. Georgiev, et al. (2004). "Gene transfer approaches in cancer immunotherapy." Gene Ther 11 Suppl 1: S18-25. Cerca con Google

79. Lee, P. P., C. Yee, et al. (1999). "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients." Nat Med 5(6): 677- 85. Cerca con Google

80. Lipponen, P. K., M. J. Eskelinen, et al. (1992). "Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer." Eur J Cancer 29A(1): 69-75. Cerca con Google

81. Lollini, P. L., F. Cavallo, et al. (2006). "Vaccines for tumour prevention." Nat Rev Cancer 6(3): 204-16. Cerca con Google

82. Ludlow, J. W. (1993). "Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53." Faseb J 7(10): 866-71. Cerca con Google

83. Masutomi, K., S. Kaneko, et al. (2002). "Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma." Oncogene 21(38): 5946-50. Cerca con Google

84. Mavroudis, D., I. Bolonakis, et al. (2006). "A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies." Oncology 70(4): 306-14. Cerca con Google

85. Mazzoni, A., V. Bronte, et al. (2002). "Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism." J Immunol 168(2): 689-95. Cerca con Google

86. Meyerson, M., C. M. Counter, et al. (1997). "hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization." Cell 90(4): 785-95. Cerca con Google

87. Mihm, M. C., Jr., C. G. Clemente, et al. (1996). "Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response." Lab Invest 74(1): 43-7. Cerca con Google

88. Mocellin, S., S. Mandruzzato, et al. (2004). "Cancer vaccines: pessimism in check." Nat Med 10(12): 1278-9; author reply 1279-80. Cerca con Google

89. Montgomery, D. L., J. W. Shiver, et al. (1993). "Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors." DNA Cell Biol 12(9): 777-83. Cerca con Google

90. Moore, A. C. and A. V. Hill (2004). "Progress in DNA-based heterologous primeboost immunization strategies for malaria." Immunol Rev 199: 126-43. Cerca con Google

91. Morgan, R. A., M. E. Dudley, et al. (2006). "Cancer regression in patients after transfer of genetically engineered lymphocytes." Science 314(5796): 126- 9. Cerca con Google

92. Muranski, P., A. Boni, et al. (2006). "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?" Nat Clin Pract Oncol 3(12): 668-81. Cerca con Google

93. Nagorsen, D., M. Panelli, et al. (2003). "Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells." Gene Ther 10(20): 1754-65. Cerca con Google

94. Nair, S. K., A. Heiser, et al. (2000). "Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells." Nat Med 6(9): 1011-7. Cerca con Google

95. Naito, Y., K. Saito, et al. (1998). "CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer." Cancer Res 58(16): 3491-4. Cerca con Google

96. Old, L. J. and E. A. Boyse (1964). "Immunology of Experimental Tumors." Annu Rev Med 15: 167-86. Cerca con Google

97. Onizuka, S., I. Tawara, et al. (1999). "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody." Cancer Res 59(13): 3128-33. Cerca con Google

98. Parkhurst, M. R., J. P. Riley, et al. (2004). "Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase." Clin Cancer Res 10(14): 4688-98. Cerca con Google

99. Pavlenko, M., A. K. Roos, et al. (2004). "A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormonerefractory prostate cancer." Br J Cancer 91(4): 688-94. Cerca con Google

100. Peng, Y., Y. Laouar, et al. (2004). "TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes." Proc Natl Acad Sci U S A 101(13): 4572-7. Cerca con Google

101. Pertmer, T. M., M. D. Eisenbraun, et al. (1995). "Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA." Vaccine 13(15): 1427-30. Cerca con Google

102. Powell, D. J., Jr., M. E. Dudley, et al. (2005). "Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy." Blood 105(1): 241-50. Cerca con Google

103. Quaglino, E., M. Iezzi, et al. (2004). "Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice." Cancer Res 64(8): 2858-64. Cerca con Google

104. Quaglino, E., S. Rolla, et al. (2004). "Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions." J Clin Invest 113(5): 709-17. Cerca con Google

105. Radi, R. (2004). "Nitric oxide, oxidants, and protein tyrosine nitration." Proc Natl Acad Sci U S A 101(12): 4003-8. Cerca con Google

106. Reiter, R. E., Z. Gu, et al. (1998). "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer." Proc Natl Acad Sci U S A 95(4): 1735-40. Cerca con Google

107. Reits, E. A., J. W. Hodge, et al. (2006). "Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy." J Exp Med 203(5): 1259-71. Cerca con Google

108. Romero, P., J. C. Cerottini, et al. (2004). "Monitoring tumor antigen specific Tcell responses in cancer patients and phase I clinical trials of peptide-based vaccination." Cancer Immunol Immunother 53(3): 249-55. Cerca con Google

109. Rosenberg, S. A., J. J. Mule, et al. (1985). "Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2." J Exp Med 161(5): 1169-88. Cerca con Google

110. Rosenberg, S. A., J. R. Yannelli, et al. (1994). "Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2." J Natl Cancer Inst 86(15): 1159-66. Cerca con Google

111. Rubinstein, N., M. Alvarez, et al. (2004). "Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege." Cancer Cell 5(3): 241-51. Cerca con Google

112. Sasada, T., M. Kimura, et al. (2003). "CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression." Cancer 98(5): 1089-99. Cerca con Google

113. Schopfer, F. J., P. R. Baker, et al. (2003). "NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response?" Trends Biochem Sci 28(12): 646-54. Cerca con Google

114. Schuler, W., I. J. Weiler, et al. (1986). "Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency." Cell 46(7): 963-72. Cerca con Google

115. Shankaran, V., H. Ikeda, et al. (2001). "IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity." Nature 410(6832): 1107-11. Cerca con Google

116. Shay, J. W. and W. E. Wright (2002). "Telomerase: a target for cancer therapeutics." Cancer Cell 2(4): 257-65. Cerca con Google

117. Sheil, A. G. (1986). "Cancer after transplantation." World J Surg 10(3): 389-96. Cerca con Google

118. Speiser, D. E., R. Miranda, et al. (1997). "Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy." J Exp Med 186(5): 645-53. Cerca con Google

119. Steinbrink, K., H. Jonuleit, et al. (1999). "Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells." Blood 93(5): 1634-42. Cerca con Google

120. Stennett, L. S., A. I. Riker, et al. (2004). "Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region." Pigment Cell Res 17(5): 525-32. Cerca con Google

121. Street, S. E., E. Cretney, et al. (2001). "Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis." Blood 97(1): 192-7. Cerca con Google

122. Stutman, O. (1974). "Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice." Science 183(124): 534-6. Cerca con Google

123. Stutman, O. (1975). "Immunodepression and malignancy." Adv Cancer Res 22: 261-422. Cerca con Google

124. Stutman, O. (1979). "Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose." J Natl Cancer Inst 62(2): 353-8. Cerca con Google

125. Su, Z., J. Dannull, et al. (2005). "Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer." J Immunol 174(6): 3798-807. Cerca con Google

126. Sussman, J. J., R. Parihar, et al. (2004). "Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion." Cancer Res 64(24): 9124-30. Cerca con Google

127. Sutmuller, R. P., L. M. van Duivenvoorde, et al. (2001). "Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses." J Exp Med 194(6): 823-32. Cerca con Google

128. Suzuki, E., V. Kapoor, et al. (2004). "Soluble type II transforming growth factorbeta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity." Clin Cancer Res 10(17): 5907-18. Cerca con Google

129. Takeda, K., M. J. Smyth, et al. (2002). "Critical role for tumor necrosis factorrelated apoptosis-inducing ligand in immune surveillance against tumor development." J Exp Med 195(2): 161-9. Cerca con Google

130. Terabe, M. and J. A. Berzofsky (2004). "Immunoregulatory T cells in tumor immunity." Curr Opin Immunol 16(2): 157-62. Cerca con Google

131. Terabe, M., S. Matsui, et al. (2000). "NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway." Nat Immunol 1(6): 515-20. Cerca con Google

132. Thornburg, C., D. Boczkowski, et al. (2000). "Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy." J Immunother (1997) 23(4): 412-8. Cerca con Google

133. Ulmer, J. B., J. J. Donnelly, et al. (1993). "Heterologous protection against influenza by injection of DNA encoding a viral protein." Science 259(5102): 1745-9. Cerca con Google

134. Uyttenhove, C., L. Pilotte, et al. (2003). "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase." Nat Med 9(10): 1269-74. Cerca con Google

135. Vandeputte, M. and P. De Somer (1965). "Influence of thymectomy on viral oncogenesis in rats." Nature 206(983): 520-1. Cerca con Google

136. Vilella, R., D. Benitez, et al. (2003). "Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine." Int J Cancer 106(4): 626-31. Cerca con Google

137. Vonderheide, R. H., S. M. Domchek, et al. (2004). "Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes." Clin Cancer Res 10(3): 828-39. Cerca con Google

138. Vonderheide, R. H., W. C. Hahn, et al. (1999). "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes." Immunity 10(6): 673-9. Cerca con Google

139. Wang, L. X., W. X. Huang, et al. (2004). "Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells." J Transl Med 2(1): 41. Cerca con Google

140. Widera, G., M. Austin, et al. (2000). "Increased DNA vaccine delivery and immunogenicity by electroporation in vivo." J Immunol 164(9): 4635-40. Wittke, F., R. Hoffmann, et al. (1999). "Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma." Br J Cancer 79(7-8): 1182-4. Cerca con Google

141. Wolf, A. M., D. Wolf, et al. (2003). "Increase of regulatory T cells in the peripheral blood of cancer patients." Clin Cancer Res 9(2): 606-12. Cerca con Google

142. Wolff, J. A., R. W. Malone, et al. (1990). "Direct gene transfer into mouse muscle in vivo." Science 247(4949 Pt 1): 1465-8. Cerca con Google

143. Workman, P., A. Balmain, et al. (1988). "UKCCCR guidelines for the welfare of animals in experimental neoplasia." Lab Anim 22(3): 195-201. Cerca con Google

144. Wrzesinski, C., C. M. Paulos, et al. (2007). "Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells." J Clin Invest 117(2): 492-501. Cerca con Google

145. Xia, Y., L. J. Roman, et al. (1998). "Inducible nitric-oxide synthase generates superoxide from the reductase domain." J Biol Chem 273(35): 22635-9. Cerca con Google

146. Xia, Y. and J. L. Zweier (1997). "Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages." Proc Natl Acad Sci U S A 94(13): 6954-8. Cerca con Google

147. Yang, D., G. E. Holt, et al. (2001). "Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice." Cancer Res 61(15): 5857-60. Cerca con Google

148. Zakian, V. A. (1997). "Life and cancer without telomerase." Cell 91(1): 1-3. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record